Clinical Trial Update: Expanded Access to ANG1005 for Individual Patients

View source ↗

Summary

Expanded access program for ANG1005 (Angiochem) for individual patients with several brain cancers; the program is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• Breast Cancer with Brain Metastases
• Leptomeningeal Carcinomatosis

Drugs mentioned

• ANG1005 (GRN1005)

Snippet

Sponsor: Angiochem Inc | Conditions: Anaplastic Astrocytoma, Anaplastic Oligodendroglioma | Status: NO_LONGER_AVAILABLE